Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Single agent, non-randomized, open label expansion in select sarcoma patients including
myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing
sarcoma; AND dose expansion of the combination of seclidemstat with topotecan and
cyclophosphamide in patients with Ewing sarcoma